Introduction
============

Angiogenesis, the formation of new blood vessels from preexisting vasculature, plays a critical role in tumor growth and metastasis [@B1]-[@B2]. To grow larger than 1-2 mm, a tumor needs sufficient blood flow, which provides oxygen and nutrients [@B3]-[@B4]. Integrins are a family of heterodimeric transmembrane receptors that are involved in multiple steps of tumor angiogenesis and metastasis. In particular, overexpression of integrins α~v~β~3~, α~v~β~5~, and α~5~β~1~ is associated with malignancy and has been shown to play various roles in tumor growth and metastasis [@B5]-[@B8]. Thus, integrin receptors have been attractive targets for developing molecular probes for non-invasive tumor imaging using different modalities including magnetic resonance imaging (MRI) [@B9], ultrasound [@B10]-[@B12], optical imaging [@B13]-[@B15], positron emission tomography (PET) [@B5], [@B16]-[@B18], and single-photon emission computed tomography (SPECT) [@B19]-[@B20].

Among the ligands that bind integrin receptors, arginine-glycine-aspartic acid (RGD)-containing peptides have been well validated for tumor imaging applications [@B21]-[@B22]. Radiofluorinated RGD probes such as ^18^F-AH111585 and ^18^F-Galacto-RGD are currently undergoing clinical studies in humans [@B16], [@B23]-[@B25]. In order to achieve higher tumor uptake, and better tumor-to-normal tissue contrasts, continued efforts to modify RGD-containing ligands remain an active area of research.

Cystine knots (also known as knottins) are small polypeptides with a common disulfide-bonded framework in which one disulfide bond threads through a macrocycle created by two other disulfide bonds and their connecting backbone segments [@B26]-[@B27], as illustrated in Figure [1](#F1){ref-type="fig"}A. As a result, knottins have a high degree of thermal and proteolytic stability and thus provide a valuable framework for development of targeting agents for *in vivo* applications [@B28]-[@B31]. Furthermore, the relatively small size of knottins (\~30-50 amino acids) makes them accessible by standard solid-phase peptide synthesis, and would result in fast blood clearance, which is desirable for molecular imaging applications.

Previously, high affinity integrin binding was conferred upon *Ecballium elaterium* trypsin inhibitor (EETI-II) using yeast surface display [@B32]. The 6-amino acid trypsin binding loop (PRILMR) of EETI-II was rationally substituted with an 11-amino-acid loop containing the RGD motif, and combinatorial methods were used to identify knottin mutants 2.5D and 2.5F, which bind to α~v~β~3~/α~v~β~5~ or α~v~β~3~/α~v~β~5~/α~5~β~1~ integrins, respectively, with high (low nM) affinity [@B32]-[@B33]. The peptide sequences of knottins 2.5D and 2.5F are shown in Figure [1](#F1){ref-type="fig"}B. Subsequently, ^64^Cu-labeled knottins were evaluated in mice bearing integrin-expressing U87MG glioblastoma xenografts, and microPET imaging and biodistribution studies showed rapid and high tumor accumulation, fast clearance from blood and normal organs, and low uptake in kidney and liver [@B33]. Overall, these studies demonstrated that engineered knottins are promising probes for molecular imaging applications.

The physical properties of ^18^F (t~½~: 110 min, emits β^+^ particles at an energy of 635 keV, 99% abundant) complement the high target binding affinity and rapid blood clearance of knottin peptides. Previously, we radiolabeled the knottin 2.5D with ^18^F via the N-terminus of the peptide using *N*-succinimidyl-4-^18^F-fluorobenzoate (^18^F-SFB), and showed that this conjugate, ^18^F-FB-2.5D, could be used to image mice bearing U87MG tumor xenografts with good tumor-to-normal tissue contrast [@B34]. To improve knottin-based probes for PET imaging and facilitate their clinical translation, we evaluated the use of an alternative ^18^F precursor, 4-nitrophenyl 2-^18^F-fluoropropionate (^18^F-NFP), which has shown enhanced metabolic stability and reduced hydrophobicity [@B16], [@B35]-[@B36]. The resulting radio probes, ^18^F-FP-2.5D and ^18^F-FP-2.5F were evaluated for tumor uptake and tissue biodistribution in nude mice bearing U87MG tumor xenografts for comparison to our previous study.

Experimental Section
====================

All commercially available materials were used as provided unless noted. All 9-fluorenylmethyloxycarbonyl (Fmoc) protected amino acids were purchased from Novabiochem/EMD Chemicals Inc (La Jolla, CA) or CS Bio (Menlo Park, CA). ^125^I-labeled echistatin was purchased from GE Healthcare Life Sciences (Piscataway, NJ). All other chemicals were purchased from Fisher Scientific (Fair Lawn, NJ) unless otherwise specified. The U87MG human glioblastoma cell line was obtained from American Type Culture Collection (Manassas, VA). Nude mice (nu/nu) were purchased from Charles River Laboratory (Wilmington, MA). Semi-preparative reversed-phase high performance liquid chromatography (RP-HPLC), using a Vydac protein and peptide column (218TP510; 5µm, 250 × 10 mm), was performed on a Dionex 680 chromatography system with a UVD 170U absorbance detector and model 105S single-channel radiation detector (Carroll & Ramsey Associates). The recorded data were processed using Chromeleon version 7.1 software. With a flow rate of 5.0 mL/min, the mobile phase was changed from 95% solvent A \[0.1% trifluoroacetic acid (TFA) in water\] and 5% B \[0.1% TFA in acetonitrile (MeCN)\] (0-2 min) to 35% solvent A and 65% solvent B at 32 min. Analytical scale HPLC used the same gradient system except that the flow rate was 1.0 mL/min with a Vydac protein and peptide column (218TP510; 5 µm, 250 × 4.6 mm). UV absorbance was monitored at 218 nm and the identification of the peptides was confirmed based on UV spectrum acquired using a photodiode array detector. Instrumentation used for matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) is the same as described in our previous publication [@B37].

**Chemistry and Radiochemistry**Peptides corresponding to the sequence of 2.5D and 2.5F were synthesized on a CS Bio CS036 Peptide Synthesizer (Menlo Park, CA) using Fmoc-based solid phase peptide synthesis. Briefly, Rink amide resin was swollen in *N,N*-dimethylformamide (DMF) for 30 min. Fmoc groups were removed with 20% piperidine in DMF. Aliquots of amino acids (1 mmol) were activated in a solution containing 1 mmol hydroxybenzotriazole (HOBt) and 0.5 M diisopropylcarbodiimide (DIC) in DMF. Following synthesis, side-chain deprotection and resin cleavage were achieved by addition of a 94:2.5:2.5:1 (v/v) mixture of TFA/triisopropylsilane/ethanedithiol/water for 2 h at room temperature. The crude product was precipitated with cold anhydrous ether, and purified using semi-preparative RP-HPLC. Peptide purity was analyzed by analytical scale RP-HPLC.

Large scale folding reactions were performed by incubating the linear peptide with 4 M guanidine, 10 mM reduced glutathione, 2 mM oxidized glutathione, and 0.5 M dimethyl sulfoxide (DMSO) at pH 7.5. The correctly folded peptide was separated from unfolded and partly folded peptides by RP-HPLC, where it appeared as a single peak with a shorter retention time than that of unfolded or misfolded precursors. Following purification, folded peptides 2.5D and 2.5F were lyophilized and stored at room temperature prior to use. Peptide purity and molecular masses were determined by analytical scale HPLC and MALDI-TOF-MS, respectively.

The synthesis of 4-nitrophenyl 2-fluoropropionate (^19^F-NFP) is briefly described below. *Bis*(4-nitrophenyl) carbonate (15.2 mg, 50.0 µmol in 20 µL of diisopropylethylamine (DIPEA)) was added to a solution of 2-fluoropropionic acid (5.0 mg, 54.3 µmol in 200 µL of DMF). After incubating at 60 °C for 3 h, the reaction mixture was cooled to room temperature and diluted with 1 mL 5% acetic acid solution. The product ^19^F-NFP was isolated by semi-preparative HPLC. The collected fractions were combined and the solvent was removed under reduced pressure. The product was obtained as white powder (5.9 mg, 56%). ESI-MS: m/z 213.1 \[M\]^+^; ^1^H NMR (CDCl~3~, 300 MHz): δ = 8.24 (d, *J* = 9.0 Hz, 2H), 7.27 (d, *J* = 9.0 Hz, 2H), 5.21 (m, 1H), 1.70 (dd, *J* = 6.8 Hz, 23.4 Hz, 3H). ^13^C NMR (CDCl~3~, 75 MHz): δ = 18.9 (d, *J* = 22.5 Hz), 86.0 (d, *J* = 184.0 Hz), 122.9, 126.0, 146.4, 155.2, 168.5.

^19^F-NFP labeled 2.5D and 2.5F (^19^F-FP-2.5D, ^19^F-FP-2.5F) were prepared as reference standards. Briefly, 2.5D or 2.5F (0.5 mg, 0.15 μmol in 400 μL of DMSO) was mixed with ^19^F-NFP (0.3 mg, 1.5 μmol in 100 μL of DMSO and 10 μL of DIPEA) and reacted for 1 h at room temperature. The resulting conjugates, ^19^F-FP-2.5D and ^19^F-FP-2.5F were then purified by semi-preparative HPLC. Fractions containing the product were collected and lyophilized. The molecular masses of ^19^F-FP-2.5D and ^19^F-FP-2.5F were confirmed by MALDI-TOF-MS. Folded peptide 2.5D: m/z = 3244.0 for \[MH\]^+^ (C~129~H~189~N~40~O~47~S~6~, calculated \[MH\]^+^ = 3244.5). Retention time on analytical scale HPLC is 16.2 min; Folded peptide 2.5F: m/z = 3292.1 for \[MH\]^+^ (C~131~H~201~N~42~O~46~S~6~, calculated \[MH\]^+^ = 3292.6). Retention time: 15.2 min; ^19^F-FP-2.5D: m/z = 3317.5 for \[MH\]^+^ (C~132~H~193~FN~40~O~48~S~6~, calculated \[MH\]^+^ = 3317.4). Retention time: 17.5 min; ^19^F-FP-2.5F: m/z 3364.9 for \[MH\]^+^ (C~134~H~203~FN~42~O~47~S~6~, calculated \[MH\]^+^ = 3365.3). Retention time: 18.3 min.

^18^F-NFP was prepared and used for knottin radiolabeling based on a previously reported procedure (Figure [1](#F1){ref-type="fig"}C) [@B38]. ^18^F-NFP (specific activity of 40-100 GBq/μmol at the end of synthesis, in 100 μL of DMSO) was added to the 2.5D or 2.5F peptide (100 μg) and 10 μL of DIPEA and reacted for 20 min at 60 °C. After adding 1 mL of water containing 50 μL of TFA to quench the reaction, the resulting conjugates were purified by semi-preparative HPLC using the same elution gradient as described for ^19^F-FP-knottin purification. The HPLC fractions containing ^18^F-FP-2.5D or ^18^F-FP-2.5F were collected, combined, and dried with a rotary evaporator. Radiolabeled peptides were reconstituted in PBS and sterilized using a 0.22 μm filter (Millipore) for *in vitro* and *in vivo* experiments.

**Cell Culture:**U87MG cells were cultured in DMEM containing high glucose (GIBCO, Carlsbad, CA), and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were expanded in tissue culture dishes and kept in a humidified atmosphere of 5% CO~2~ at 37 °C, with media changes every other day. Confluent monolayers were detached with 0.05% Trypsin-EDTA, 0.01M PBS (pH 7.4) and dissociated into single-cell suspensions for further cell culture and experimentation.

**U87MG Cell Binding Assay:**Cell binding assays were performed as previously described [@B37], [@B39]. Briefly, 2 × 10^5^ U87MG cells were incubated with 0.06 nM ^125^I-labeled echistatin and varying concentrations of peptides (2.5D, 2.5F, ^19^F-FP-2.5D or ^19^F-FP-2.5F) in integrin binding buffer \[25 mM Tris pH 7.4, 150 mM NaCl, 2mM CaCl~2~, 1 mM MgCl~2~, 1 mM MnCl~2~, and 0.1% bovine serum albumin (BSA)\] at room temperature for 3 h. The cell-bound radioactivity remaining after washing was measured by gamma-counting. Half-maximal inhibitory concentration (IC~50~) values were determined by nonlinear regression using GraphPad Prism (GraphPad Software, Inc.). Experiments were performed with quadruplicate samples.

**MicroPET Imaging:**All animal studies were carried out in compliance with Federal and local institutional regulations for the conduct of animal experimentation. Approximately 10 × 10^6^ U87MG cells were suspended in 100 µL of PBS and subcutaneously implanted in the right shoulders of nude mice. Tumors were grown to a size of 0.5 cm in diameter (approximately 2-3 weeks). MicroPET scans were performed on a microPET R4 rodent model scanner (Concorde Microsystems Inc.). The scanner has a computer-controlled bed and 10.8-cm transaxial and 8-cm axial fields of view (FOVs). It has no septa and operates exclusively in the 3-dimensional (3D) list mode. Mice bearing U87MG xenografts were injected via tail vein with approximately 3.7 MBq (100 μCi) of ^18^F-FP-2.5D or ^18^F-FP-2.5F, with or without 10 mg/kg mouse body weight c(RGDyK). At 0.5, 1, and 2 h post injection (p.i.) mice were anesthetized with isoflurane (5% for induction and 2% for maintenance in 100% O~2~). With the help of a laser beam attached to the scanner, mice were placed in the prone position and near the center of the field of view of the scanner where the image resolution and sensitivity is highest. Three minute static scans were obtained, and images were reconstructed by use of a 2-dimensional ordered-subsets expectation maximization (OSEM) algorithm. No background correction was performed. Region of interests (ROIs) were drawn over the tumor on decay-corrected whole-body coronal images. The maximum counts per pixel per minute were obtained from the ROI and converted to counts per milliliter per minute by using a calibration constant. Based on the assumption of a tissue density of 1 g/ml, ROIs were converted to counts per gram per min. The percent injected dose per gram of tissue (%ID/g) was determined by dividing counts per gram per minute by injected dose. No attenuation correction was performed.

**Animal Biodistribution Studies:**For biodistribution studies, nude mice bearing U87MG xenografts (n = 3 for each group) were injected via tail vein with approximately 3.7 MBq (100 μCi) of ^18^F-FP-2.5D or ^18^F-FP-2.5F, with or without 10 mg/kg mouse body weight c(RGDyK). Mice were sacrificed at 2 h p.i., and tumor and normal tissues of interest were removed and weighed, and their radioactivity was measured in a gamma-counter. The radioactivity uptake in the tumor and normal tissues was expressed as % ID/g.

**Statistical Method:**Statistical analysis was performed using the Student\'s *t*-test for unpaired data. A 95% confidence level was chosen to determine the significance between groups, with *P* \< 0.05 being designated as significantly different.

Results
=======

**Chemistry and Radiochemistry:**Peptides 2.5D and 2.5F were synthesized via solid phase peptide synthesis, followed by oxidative folding with a mixture of glutathione and DMSO. The final products were purified by semi-preparative RP-HPLC to achieve greater than 95% purity. Non-radioactive ^19^F analogs were used as standards for radiosynthesis and for cell binding assays. ^19^F-FP-2.5D and ^19^F-FP-2.5F were prepared by direct conjugation of ^19^F-NFP to knottin peptides 2.5D or 2.5F with yields of 92% and 95%, respectively. Product purities of greater than 95% were achieved as determined by analytical scale HPLC. MALDI-TOF-MS confirmed correct molecular masses for all peptides used in this study.

The total synthesis time for ^18^F-NFP was approximately 100 min using a modified GE synthetic module (TRACERlab FX~FN~) with decay corrected yields of 67 ± 11% (n = 10, Figure [1](#F1){ref-type="fig"}C) [@B36], [@B38]. The decay-corrected radiochemical yields of ^18^F-FP-2.5D and ^18^F-FP-2.5F based on ^18^F-NFP were 12.0 ± 2.7% and 10.5 ± 1.8% (n = 4), respectively. The radiochemical purities of ^18^F-FP-2.5D and ^18^F-FP-2.5F were greater than 99% according to analytical scale HPLC. The specific radioactivity of ^18^F-FP-2.5D and ^18^F-FP-2.5F was estimated to be 20-40 GBq/µmol at the end of synthesis.

***In Vitro* Cell Receptor-Binding Assay:**Integrin positive U87MG human glioblastoma cells were used for binding studies. Binding affinities of 2.5D, 2.5F, ^19^F-FP-2.5D and ^19^F-FP-2.5F were determined by competitive displacement of ^125^I-echistatin, a potent integrin binder, from U87MG cells. All peptides inhibited the binding of ^125^I-echistatin to U87MG cells in a concentration-dependent manner. The IC~50~ values for ^19^F-FP-2.5D and ^19^F-FP-2.5F were 7.4 ± 1.9 and 7.5 ± 1.3 nM, respectively (n = 4) (Figure [2](#F2){ref-type="fig"}). Comparison of binding values to unlabeled 2.5D and 2.5F (IC~50~ values = 6.9 ± 1.4 and 6.1 ± 1.6 nM, respectively) showed that fluoropropionate conjugation did not interfere with integrin receptor binding.

**MicroPET Imaging Study:**Static microPET scans were performed on U87MG tumor-bearing mice and representative decay-corrected coronal images at 0.5, 1, and 2 h after tail vein injection of ^18^F-FP-2.5D or ^18^F-FP-2.5F are shown in Figure [3](#F3){ref-type="fig"} (n = 3 for each group). U87MG tumors were clearly visualized, as both tracers produced excellent tumor-to-background contrast. MicroPET quantification of tumors and other organs was obtained from ROI analysis and the results at 0.5, 1, and 2 h p.i. are shown in Figure [4](#F4){ref-type="fig"}A and B. No significant difference in tumor uptake between these two probes was observed at each time point (*P* \> 0.05). For ^18^F-FP-2.5D, tumor uptake was 3.30 ± 1.08, 2.86 ± 1.11, and 2.37 ± 1.13 %ID/g at 0.5, 1, and 2 h p.i., respectively. For ^18^F-FP-2.5F, tumor uptake was 3.74 ± 0.88, 3.60 ± 0.25, and 1.71 ± 0.37 % ID/g at 0.5, 1, and 2 h p.i., respectively. Both probes were cleared rapidly from the blood, and moderate to low renal retention was observed (4.24 ± 1.94, 2.81 ± 1.42, and 2.68 ± 2.90 %ID/g for ^18^F-FP-2.5D at 0.5, 1, and 2 h p.i.; 13.39 ± 1.15, 5.25 ± 0.65, and 2.51 ± 0.16 %ID/g for ^18^F-FP-2.5F at 0.5, 1, and 2 h p.i.). Interestingly, liver uptake of ^18^F-FP-2.5F was significantly higher than ^18^F-FP-2.5D at 0.5 h p.i., (*P* \< 0.05), while no significant difference was observed at 1 h and 2 h p.i. Nonspecific uptake in the muscle was very low for both probes (0.51 ± 0.30 %ID/g and 0.44 ± 0.08 %ID/g for ^18^F-FP-2.5D and ^18^F-FP-2.5F at 2 h p.i., respectively). Gallbladder uptake of ^18^F-FP-2.5D and ^18^F-FP-2.5F was 0.86 ± 0.33 and 1.08 ± 0.41 %ID/g at 2 h p.i., respectively; these values were similar to background muscle uptake level. Tumor-to-normal tissues ratios of both probes at 0.5, 1, and 2 h were calculated and are shown in Figure [4](#F4){ref-type="fig"}C. At 0.5 h p.i., ^18^F-FP-2.5D had higher tumor to liver, kidneys, and muscle ratios than those of ^18^F-FP-2.5F (*P* \< 0.05). This is consistent with the better tumor image quality of ^18^F-FP-2.5D compared to ^18^F-FP-2.5F at early time points (0.5 and 1 h p.i.), shown in Figure [3](#F3){ref-type="fig"}A and C.

The integrin targeting specificity of both probes was demonstrated by co-injection of an excess of c(RGDyK) as a blocking agent. Figure [3](#F3){ref-type="fig"}B and D show the microPET images of ^18^F-FP-2.5D and ^18^F-FP-2.5F at 0.5, 1, and 2 h p.i. with co-injection of c(RGDyK). The corresponding microPET quantification results are shown in Figure [4](#F4){ref-type="fig"}. Coinjection of c(RGDyK) resulted in significant decreases in tumor uptake for both ^18^F-FP-2.5D (3.91 ± 0.15 %ID/g without blocking *vs.*1.96 ± 0.07 %ID/g with blocking, *P* \< 0.05) and ^18^F-FP-2.5F (3.83 ± 0.51 %ID/g without blocking *vs.* 1.90 ± 0.21 %ID/g with blocking, *P* \< 0.05).

**Biodistribution Studies:**To validate microPET imaging experiments, biodistribution studies of ^18^F-FP-2.5D and ^18^F-FP-2.5F were performed at 2 h p.i. in U87MG xenograft models. Probe uptake in tumors and other major organs was calculated and is shown in Figure [5](#F5){ref-type="fig"}. No significant differences were observed compared to microPET image quantification. In these studies, the *in vivo*tumor targeting specificity of the probes was further confirmed by co-injection of an excess of c(RGDyK) blocking agent. A significant decrease in tumor uptake was observed for both ^18^F-FP-2.5D (1.92 ± 0.65 %ID/g *vs.* 1.06 ± 0.10 %ID/g, *P* \< 0.05) and ^18^F-FP-2.5F (2.24 ± 0.60 %ID/g *vs.* 1.25 ± 0.10 %ID/g, *P* \< 0.05) upon co-injection with c(RGDyK).

Discussion
==========

Probe development is a central theme in cancer-specific molecular imaging applications. Historically, it has been challenging and time consuming to develop probes that bind tumor-related receptors with high affinity and specificity [@B40]-[@B42]. Numerous efforts have sought to generalize binder development using a variety of molecular platforms. Recently, small protein scaffolds have become robust starting points for molecular probe development [@B39], [@B43]-[@B44]. Knottins, which are generally 3-5 kDa in size, are highly stable scaffolds that have been shown to be amenable to rational and combinatorial engineering. Moreover, knottin engineering methods are maturing as new binders are being developed based on this versatile framework [@B30], [@B45]. Recently, high-affinity integrin-binding knottins were successfully identified by yeast display technology [@B32]-[@B33]. Radiolabeled knottins, using ^64^Cu or ^18^F for PET imaging, have shown great promise for imaging integrin expression in mouse tumor models [@B31], [@B44], [@B46].

In this study, we evaluated ^18^F-FP-labeled knottin 2.5D and 2.5F and explored potential advantages over ^18^F-FB analogs, including effects on tumor uptake and retention and uptake in non-target organs. ^18^F-fluoropropionate was chosen because it has relatively higher *in vivo* metabolic stability compared to ^18^F-fluorobenzoate, as indicated by a high percentage of intact ^18^F-FP-labeled probe in a metabolite analysis [@B38]. Moreover, ^18^F-fluoropropionate is a less hydrophobic tag than that of ^18^F-fluorobenzoate. Methods for radiosynthesis of ^18^F-NFP have also been well established [@B38], [@B47]-[@B48]. Importantly, ^18^F-NFP is practically the smallest ^18^F-radiolabeling group for peptides, and is currently being used in clinical trials in human subjects [@B16], [@B23], [@B35].

Figure [4](#F4){ref-type="fig"}A and B show the results of microPET image quantification of ^18^F-FP-2.5D and ^18^F-FP-2.5F, which exhibit rapid tumor targeting and good tumor retention. Both probes exhibited maximum tumor uptake at 0.5 h p.i., and sustained tumor accumulation was observed. For example, at 1 and 2 h p.i., tumor uptake values were 2.86 ± 1.11 and 2.37 ± 1.13 %ID/g for ^18^F-FP-2.5D, and 3.60 ± 0.25 and 1.71 ± 0.37 %ID/g for ^18^F-FP-2.5F, respectively. Comparatively, the previously published knottin, ^18^F-FB-2.5D demonstrated lower tumor uptake of 1.46 ± 0.35 %ID/g at 1 h p.i. [@B34]. Furthermore, gallbladder uptake was lower for ^18^F-FP-2.5D (1.17 ± 0.47 %ID/g at 1 h p.i.), compared to ^18^F-FB-2.5D (2.82 ± 1.31 %ID/g), which could be due to lower *in vivo* stability of ^18^F-FB compared to ^18^F-FP. For example, in a previous study, high *in vivo* stability was reported for a ^18^F-FP labeled RGD dimer; more than 95% of the ^18^F-labeled RGD dimer was shown to be intact at 2 h p.i. [@B38]. Importantly, ^18^F-FP-2.5D had higher tumor-to-normal tissue ratios than ^18^F-FB-2.5D, thus the ^18^F-FP label resulted in improved imaging quality. Tumor-to-organ ratios for liver, kidneys, lungs, and gallbladder were 2.56 ± 0.55, 0.83 ± 0.28, 3.74 ± 0.70, and 2.53± 0.39, respectively, at 0.5 h p.i. for ^18^F-FP-2.5D. In comparison, ratios for the same organs for ^18^F-FB-2.5D were 1.97 ± 0.75, 0.50 ± 0.16, 2.03 ± 0.40, and 0.71 ± 0.32, respectively (Figure [4](#F4){ref-type="fig"}C). Collectively, these results highlight advantages of using a FP prosthetic group versus FB for knottin radiolabeling and *in vivo* imaging.

The IC~50~ values of knottin 2.5D and 2.5F indicated higher affinity integrin binding compared to that of a cyclic RGD pentapeptide (c(RGDyK)) published in the literature [@B49]; however, the tumor uptake for these probes were similar. For example, the U87MG tumor uptake of ^18^F-FB labeled c(RGDyK) was 2.56 ± 0.12 %ID/g [@B50], compared to tumor uptake values of 2.24 ± 0.60 %ID/g for ^18^F-FP-2.5F at 2 h p.i. in the biodistribution study. These results indicate that the *in vivo* performance of a peptide-based molecular imaging probe depends on not only binding affinity, but other parameters such as charge, size, or hydrophobicity.

^64^Cu-labeled knottin 2.5D and 2.5F analogs had similar tumor and normal tissue uptake, which resulted in comparable microPET contrast. However, different contrasts were observed for ^18^F-FP-2.5D and ^18^F-FP-2.5F (Figure [3](#F3){ref-type="fig"}A and C). ^18^F-FP-2.5D showed better image quality compared to ^18^F-FP-2.5F at 0.5 and 1 h p.i., but at a later time point (2 h p.i.), the tumor-to-muscle ratios for ^18^F-FP-2.5D and ^18^F-FP-2.5F reached the same level. Despite having similar binding affinities, the amino acid residues flanking the RGD motif in the engineered integrin binding loops of 2.5D and 2.5F are very different (Figure [1](#F1){ref-type="fig"}B), which may have influenced their *in vivo* behavior in this study. These results further indicate the importance of evaluating different radiolabeling methods in order to optimize the *in vivo* performance of protein- or peptide-based imaging probes.

PET provides a sensitive technique to identify and characterize disease in living systems. For a newly-developed PET probe to be successfully translated into the clinic, it should have high tumor uptake with reasonable tumor-to-background ratios in support of clinical radioisotopes with relatively short half-lives, such as ^18^F. The PET probe should also be able to be prepared in high radiochemical yield, purity, and specific activity. The total radiosynthesis time for ^18^F-FP-2.5D and ^18^F-FP-2.5F was approximately 100 minutes. Furthermore, the ^18^F-FP labeled knottins developed here meet some of these basic criteria such as high labeling yield, high *in vivo* stability, high radiochemical purity and good tumor uptake with high tumor-to-background ratios. Together, these results suggest that ^18^F-FP-2.5D, and potentially ^18^F-FP-2.5F, may have clinical potential for integrin imaging.

In conclusion, radiolabeled knottin peptides, ^18^F-FP-2.5D and ^18^F-FP-2.5F showed integrin-specific PET imaging of U87MG tumors marked by good contrast, fast tumor targeting, rapid clearance from body and relatively low uptake in normal tissues. The ^18^F-FP-labeled knottin mutant 2.5D exhibited higher tumor-to-normal tissue contrast compared to ^18^F-FB-2.5D, perhaps due to increased *in vivo* stability of ^18^F-FP residue. Taken together, these results suggest that ^18^F-FP-2.5D may perform well in clinical applications.
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![Schematic and sequences of knottin peptides. (A) Cartoon representation of a radiofluorinated knottin peptide scaffold. The imaging label ^18^F-NFP was site-specifically conjugated to the N-terminus of the knottin. (B) Amino acid sequences of knottin peptides 2.5D and 2.5F with disulfide bonds between Cys1-Cys4, Cys2-Cy5, and Cys3-Cys6. (C) Synthetic scheme for ^18^F-NFP synthon and knottin radiofluorination.](thnov01p0403g01){#F1}

![Competition binding of ^125^I-echistatin to integrin receptors expressed on U87MG cells by 2.5D, 2.5F, ^19^F-FP-2.5D, or ^19^F-FP-2.5F. Results expressed as percentage of ^125^I-echistatin binding are the mean of quadruplicate measurements ± standard deviation. \[M\] = peptide molar concentration](thnov01p0403g02){#F2}

![(A) and (C) Coronal microPET images of U87MG tumor-bearing mice at 0.5, 1, and 2 h post injection of approximately 3.7 MBq (100 µCi) of ^18^F-FP-2.5D or ^18^F-FP-2.5F, respectively. (B) and (D) Coronal microPET images of U87MG tumor-bearing mice at 0.5, 1, and 2 h after co-injection of approximately 3.7 MBq (100 µCi) of ^18^F-FP-2.5D and ^18^F-FP-2.5F with 10 mg c(RGDyK) per kg mouse body weight, respectively. Red arrows indicate tumors.](thnov01p0403g03){#F3}

![(A) and (B) MicroPET quantification results, expressed as %ID/g, in tumor and organs of U87MG xenograft models after intravenous injection of \~3.7 MBq ^18^F-FP-2.5D or ^18^F-FP-2.5F, respectively. (C) Tumor/nontumor (T/NT) ratios at 0.5, 1 and 2 h p.i. were calculated from A and B. GB = Gallbladder.](thnov01p0403g04){#F4}

![Biodistribution of ^18^F-FP-2.5D or ^18^F-FP-2.5F in U87MG tumor-bearing mice at 2 h after injection with or without co-injection of 10 mg/kg of c(RGDyK) as a blocking agent. Data are expressed as %ID/g ± SD (n = 3 per group).](thnov01p0403g05){#F5}
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